Clinical Trial Update: Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates thymosin alpha-1 in combination with standard of care as maintenance therapy for patients with metastatic non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Thymosin alpha-1 (thymosin alpha-1)

Snippet

Sponsor: SciClone Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN